Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Gw799251X SCHEMBL3898645 | 1.00 | EGFR (1.00) | EGFRERBB2 | |
| SCHEMBL5922666 | 0.90 | EGFR (0.82) | EGFRERBB2 | |
| SCHEMBL3900665 | 0.88 | EGFR (0.79) | EGFRERBB2 | |
| SCHEMBL3964814 | 0.87 | EGFR (1.00) | EGFRERBB2 | |
| SCHEMBL5922751 | 0.87 | EGFR (1.00) | EGFRERBB2 | |
| Gw659893X SCHEMBL5922876 | 0.86 | EGFR (1.00) | EGFRERBB2 | |
| Gw659893X SCHEMBL30467443 | 0.86 | EGFR (1.00) | EGFRERBB2 | |
| SCHEMBL5922713 | 0.86 | EGFR (1.00) | EGFRERBB2 | |
| SCHEMBL3968852 | 0.86 | EGFR (0.78) | EGFRERBB2 | |
| SCHEMBL3897471 | 0.86 | EGFR (1.00) | EGFRERBB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230190748-A1 | COMPOSITIONS FOR TREATMENT OF AGED DISEASES | GERO PTE LTD (SG) | 2023-06-22 | — | — | US | claimed |
| US-20230190748-A1 | COMPOSITIONS FOR TREATMENT OF AGED DISEASES | GERO PTE LTD (SG) | 2023-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230190748-A1 | COMPOSITIONS FOR TREATMENT OF AGED DISEASES | AGER, CKMT1A; CKMT1B, GLA | EGFR 1153/4885ERBB2 1599/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.